Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects
Status:
Terminated
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
Lung infections are a chronic problem for patients with cystic fibrosis (CF). Some patients
with CF may have a type of bacteria called Pseudomonas aeruginosa in their lungs that can
cause infections or make their symptoms worse. Tobramycin inhalation solution (TOBI) is an
approved antibiotic, which is inhaled directly into the lungs, and can be used to manage
these infections. Tobramycin inhalation powder (TIP) is a new, experimental powder
formulation of tobramycin that is inhaled directly into the lungs using a T-326 inhaler. The
purpose of this research study is to determine if TIP is safe and effective when compared to
placebo (a powder with no medicine) treatment.